Fusobacterium nucleatum and IL-32 co-predict nodal metastasis preoperatively in head and neck cancer

核梭杆菌和IL-32共同预测头颈癌术前淋巴结转移

阅读:1

Abstract

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with high rate of lymph node metastasis (LNM), which significantly impacts prognosis. This study aims to evaluate the potential utility of Fusobacterium nucleatum (F. nucleatum) and interleukin-32 (IL-32) as co-predictors for cervical LNM in HNSCC, enhancing preoperative assessment of metastatic status in patients. METHODS: Clinical information, tissue, and plasma samples were collected from a cohort of 254 HNSCC patients. IL-32 expression was assessed using immunohistochemistry (IHC), while fluorescence in situ hybridization (FISH) was used to evaluate F. nucleatum enrichment in both tumor and paracancer tissue. Univariate and multivariate analyses identified significant risk factors. RESULTS: IL-32 levels were higher in tumor tissue compared to paracancer tissue (P<0.001). Patients with high F. nucleatum enrichment had higher IL-32 expression (P=0.04). Through univariate and multivariate analyses, alcohol, Ki-67 (antigen Kiel-67) expression, F. nucleatum enrichment and IL-32 expression were identified as significant risk factors of LNM. The comparison of receiver operating characteristic (ROC) curves for these factors showed that the combined use of all chosen indicators resulted in the highest diagnostic accuracy. CONCLUSIONS: The enrichment of F. nucleatum in cancer tissue is positively correlated with high expression of IL-32, suggesting that these two novel indicators, F. nucleatum and IL-32, along with Ki-67 and alcohol, may serve as preoperative predictors for LNM in HNSCC. This discovery holds great potential to facilitate the development of more precise and personalized surgical strategies for patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。